Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limted

Jazz Pharmaceuticals, Inc.

today announced that the Jazz Pharmaceuticals stockholders have approved all of the proposals submitted for approval at today's stockholder meeting, including the proposal to approve the combination of the businesses of Jazz Pharmaceuticals and Azur Pharma. Once the transaction is closed, the Jazz Pharmaceuticals and Azur Pharma businesses will operate as a combined company, Jazz Pharmaceuticals plc, a company domiciled in Ireland. Approximately 99.86% of the votes cast by Jazz Pharmaceuticals' stockholders were cast in favor of the merger agreement. Jazz Pharmaceuticals currently anticipates that the transaction will close in January 2012. Following the closing, Jazz Pharmaceuticals plc will be listed on the Nasdaq stock exchange under Jazz Pharmaceuticals' current ticker symbol, "JAZZ."